Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to UCL and Ludwig Institute.

iTeos Therapeutics, a US-based immuno-oncology drug spinout of Universit√© catholique de Louvain (UCL) and Ludwig Institute for Cancer Research, raised more than $201m in a listing on Friday. The company priced its shares at $19, above its previous target of $18, and upped the number of shares by approximately 350,000 to 10.58 million. It has…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.